Evidence map›Paper›PMID 21356346›Full record

ReviewThe American journal of pathology2011

Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance.

Steven J Wang, Lilly Y W Bourguignon

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 142 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Steven J WangDepartment of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, California 94115, USA. swang@ohns.ucsf.edu
Lilly Y W Bourguignon
San Francisco VA Medical Center · USUniversity of California, San Francisco · US

Funding

RELATIONSHIP OF PERMEABILITY BARRIER FUNCTION AND EPIDERMAL CYTOKINE PRODUCTIONP01AR039448 · NIAMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI ELIAS, PETER M · 1988 to 2007
$11.8M
CD44/VARIANT CYTOSKELETON IN BREAST CANCER PROGRESSIONR01CA066163 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BOURGUIGNON, LILLY YW · 1995 to 2010
$2.6M
CD44-P185HER2 INTERACTION IN OVARIAN CANCER PROGRESSIONR01CA078633 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BOURGUIGNON, LILLY YW · 1999 to 2007
$2.5M
NCI NIH HHS R01 CA066163NCI NIH HHS R01 CA078633NCI NIH HHS R01 CA66163NCI NIH HHS R01 CA78633NIAMS NIH HHS P01 AR039448NIAMS NIH HHS P01 AR39448
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy that may involve the oral cavity, pharynx, larynx, and paranasal sinuses. The mechanisms of tumor progression underlying the clinical behavior of HNSCC remain unclear. CD44 comprises a family of transmembrane receptors that can give rise to multiple CD44 variant isoforms. Hyaluronan (HA), a major extracellular matrix component is the primary ligand for CD44 receptors. HA and CD44 signaling play an important role in HNSCC progression. Several CD44 variant isoforms (including v3-, v6-, and v10-containing isoforms) are associated with advanced disease, possibly through unique growth factor interactions with binding domains in the inserted variant regions of the cytoplasmic domain of CD44. In HNSCC, HA mediates the formation of a complex including CD44 and the epidermal growth factor receptor (EGFR) which is overexpressed in a large proportion of HNSCCs. Downstream effectors under EGFR regulation are activated, promoting promote cell growth and tumor survival. The leukemia-associated Rho-guanine nucleotide exchange factor (LARG) also associates with CD44 and EGFR to promote several Ras and RhoA pathway effectors, leading to cell migration, growth, and tumor survival. The secretion of matrix metalloproteinases, necessary for tumor cell invasion, is also regulated by these HA/CD44-mediated pathways. Finally, EGFR-mediated pathways play major roles in the HA/CD44 promotion of chemoresistance in HNSCC. Understanding HA/CD44-mediated signaling pathways may lead to improved treatment of HNSCC.

Indexed as

Disease ProgressionDrug Resistance, NeoplasmSignal TransductionCarcinomaCarcinoma, Squamous CellHead and Neck NeoplasmsHumansHyaluronan ReceptorsHyaluronic AcidNeoplasms, Squamous CellSquamous Cell Carcinoma of Head and NeckHyaluronan ReceptorsHyaluronic Acid

Identifiers

PMID21356346
PMCPMC3069910
OpenAlexW1982947486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.